Pharmaceuticals, Biotechnology & Life Sciences

Alnylam gains Outperform ratings as BMO & Benzinga boost its RNAi‑powered ATTR pipeline, positioning the biotech stock for strong growth.

Arcturus Therapeutics: Is its RNA‑based promise worth the steep volatility? Dive into the latest financial data, market risks, and future prospects for this San Diego‑based biotech.

Roche’s $750 million U.S. plant expansion in Oregon doubles Genentech’s drug‑manufacturing capacity, while a CHF 410 million bond fuels global R&D and growth plans.

Teva’s FDA acceptance of Ecopipam opens a new specialty drug frontier, while patent wins and a Turkish probe test its generics dominance.

Oncolytics Biotech secures FDA dialogue for its REOLYSIN therapy targeting RAS‑mutant MSS colorectal cancer, boosting clinical trial prospects and investor confidence.

Explore how Novo Nordisk’s Wegovy surge, regulatory risks and rivals like Eli Lilly shape its future growth and market strategy.

Explore Zhangzhou Pientzehuang Pharmaceutical—China’s top TCM maker—market cap $76.8B, high‑growth stock, and flagship cough syrups blending tradition with innovation.

Pfizer’s 4% stock rally sparks concerns as a $1.2 billion Depo‑Provera settlement and a lagging R&D pipeline threaten the company’s high valuation and investor confidence.

Altimmune Inc: navigating biotech volatility while pioneering peptide therapeutics for obesity, NASH and chronic hepatitis B, with stock under pressure but high potential upside.

Moderna’s stock soars 170% after breakthrough melanoma mRNA vaccine results, then pulls back as analysts weigh valuation risks and future potential.